Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753258 | 0.91 | ABCG2 (0.53) | MAPK1CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL5754227 | 0.86 | CYP1A2 (0.49) | MAPK1CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL5753205 | 0.75 | ABCG2 (0.55) | MAPK1CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL5749757 | 0.75 | ABCG2 (0.45) | MAPK1CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL5752653 | 0.74 | MEN1 (0.56) | MAPK1CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL5753106 | 0.72 | KDR (0.41) | MAPK1CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL5752197 | 0.70 | CA9 (0.45) | MAPK1CYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL21490327 | 0.69 | MAPT (0.67) | MAPK1MEN1KMT2ALMNATSHR | |
| SCHEMBL5753112 | 0.68 | TRPV1 (0.52) | MAPK1LMNAMAPTKDM4ETRPV1 | |
| SCHEMBL6033057 | 0.68 | TRPV1 (0.55) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | NEUROGEN CORPORATION (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | TRPV1, GPR17, TRPV2 | MAPK1 3408/4885CYP1A2 2438/4885CYP3A4 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.